Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Shingrix, the only shingles vaccine available in the United States, is not a live virus vaccine; it is a recombinant, adjuvanted vaccine that uses a single viral protein plus an immune booster, given as two doses. The older option, Zostavax, was a live attenuated vaccine that was discontinued in the U.S. in November 2020, which is why people who are immunocompromised can now be vaccinated when they previously could not. Eligibility, timing between doses, and what to expect for side effects differ by age and immune status, and there are several important details to consider. See below for the complete answer, including who should get vaccinated and what to do if you already received Zostavax.
If you are weighing vaccination because of a painful rash, tingling, or burning skin that is already developing, timing matters, since antiviral treatment for shingles works best within the first 72 hours of symptoms. A free, instant, online symptom check can help you sort out whether what you are feeling looks like shingles, a different rash, or nerve pain, and point you toward the right next step and level of care.
Last reviewed for medical accuracy: 10/01/2026
Is the shingles vaccine a live virus? What changed with Shingrix?
Shingles (herpes zoster) is a painful rash caused by reactivation of the chickenpox virus (varicella-zoster virus) in people who’ve had chickenpox before. Vaccination is the best way to prevent shingles and its complications. You may wonder, “Is the shingles vaccine a live virus?” The answer depends on which vaccine you’re looking at. Below, you’ll find clear, concise information—backed by the Centers for Disease Control and Prevention (CDC) and other credible sources—about the two main shingles vaccines, how they work, and why Shingrix represents a major advance.
Zostavax® (Live-Attenuated Vaccine)
Shingrix® (Recombinant Subunit Vaccine)
Key takeaway: If you’re asking “is the shingles vaccine a live virus,” the answer is “it depends.” Zostavax is live-attenuated; Shingrix is non-live (recombinant).
When Shingrix was introduced, it quickly became the preferred shingles vaccine for these reasons:
Higher Efficacy
Longer-Lasting Protection
Safety Profile
Broader Eligibility
Q: Can I get Shingrix if I already had Zostavax?
A: Yes. The CDC advises that people previously vaccinated with Zostavax still get Shingrix for stronger, longer-lasting protection. Wait at least 8 weeks after Zostavax before starting Shingrix.
Q: Do I need a live-virus vaccine if I’m immune-compromised?
A: No. In many cases, Shingrix (non-live) is a safer choice for people with certain immune conditions. Always discuss your specific health situation with your doctor.
Q: What if I’ve had shingles before?
A: Even if you’ve had shingles, Shingrix can help prevent future episodes. Talk to your doctor about timing—typically you wait until the rash has cleared.
Most people tolerate Shingrix well. Common reactions include:
These effects usually peak within 1–2 days and resolve quickly. If you experience severe or persistent symptoms, contact your healthcare provider.
Vaccination decisions are personal and should be made in consultation with your healthcare professional. If you’re unsure about your symptoms or need personalized guidance, consider doing a
free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to help you decide whether to seek medical care.
This information is intended to help you make informed decisions. Nothing here replaces personalized medical advice. If you have any concerns—particularly anything that could be serious or life threatening—please speak to a doctor right away.
(References)
* Gelb LD. Reducing the incidence and severity of herpes zoster and PHN with zoster vaccination. J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S18-21. PMID: 19553631.
* Cogman AR, Chakravarty EF. The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine. 2013 Aug 12;31(36):3640-3. doi: 10.1016/j.vaccine.2013.05.085. Epub 2013 Jun 3. PMID: 23742992; PMCID: PMC3952213.
* Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014 Oct;59(7):920-2. doi: 10.1093/cid/ciu501. Epub 2014 Aug 4. PMID: 25097080.
* Whitley RJ. Editorial commentary: Waning efficacy of the herpes zoster vaccine. Clin Infect Dis. 2015 Mar 15;60(6):910-1. doi: 10.1093/cid/ciu922. Epub 2014 Nov 20. PMID: 25416752.
* Oxman MN, Harbecke R, Koelle DM. Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine. J Infect Dis. 2017 Dec 12;216(11):1329-1333. doi: 10.1093/infdis/jix484. PMID: 29029303; PMCID: PMC5853975.
* Morgado-Carrasco D, Fustà-Novell X, Giavedoni P. RF-New Recombinant Vaccine for the Prevention of Herpes Zoster. Actas Dermosifiliogr (Engl Ed). 2020 Jan 2;111(1):67-68. doi: 10.1016/j.ad.2018.06.020. Epub 2019 Aug 3. PMID: 31387689.
* Lu PJ, Hung MC, Srivastav A, Williams WW, Dooling KL. Shingles Vaccination of U.S. Adults Aged 50-59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine. Am J Prev Med. 2020 Jul;59(1):21-31. doi: 10.1016/j.amepre.2020.01.017. Epub 2020 May 7. PMID: 32389533; PMCID: PMC9196997.
* Callegaro A, Burny W, Hervé C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine. J Infect Dis. 2022 Nov 28;226(11):1943-1948. doi: 10.1093/infdis/jiab536. PMID: 34662415; PMCID: PMC9704432.
* Kupa LVK, Medeiros-Ribeiro AC, Aikawa NE, Pasoto SG, Borba EF, Assad APL, Saad CGS, Yuki EFN, Seguro LPC, Andrade D, Shinjo SK, Sampaio-Barros PD, Shimabuco AY, Moraes JCB, Sampaio VS, Giardini HAM, Silva CAA, Bonfá E. Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study. J Clin Rheumatol. 2025 Sep 1;31(6):e104-e111. doi: 10.1097/RHU.0000000000002216. Epub 2025 Mar 4. PMID: 40036115.
* Ark R, Allen V, Bechman K, Yang Z, Nagra D, Russell MD, Galloway J. Shingles vaccination in immune-mediated inflammatory diseases: a narrative review. Rheumatology (Oxford). 2026 Feb 4;65(2). doi: 10.1093/rheumatology/keag043. PMID: 41578947.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.